Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

Shell Canada's decision on whether to pursue Phase 2 of LNG Canada will depend on other opportunities that are available, ...

Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

GLP-1 drugs like Ozempic are associated with a higher risk of developing wet age-related macular degeneration in people with ...

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision ...

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.